Longevity
Live tracking
Cellular Reprogramming Approved Therapy
FDA-approved partial cellular reprogramming therapy that resets cells to a younger epigenetic state.
Evidence:clinicaltrialsarxiv Source refresh pending
37%progress
Median Predicted Year
2036
P10: 2030 · P90: 2045
Time to Median Prediction
Syncing countdown…
Progress Index Over Time
Proprietary progress score
Prediction Range
P10 / Median / P90 estimates
expertmarketmodel
Why It Moved — Recent Events
20 days laterAug 20
Hourly data refresh: 30 active clinical trials.
Automated data refresh
50 days soonerJul 30
Hourly data refresh: 31 active clinical trials. 98 new papers in last 30 days.
Automated data refresh
Accelerators & Bottlenecks
What speeds it up
Life Biosciences first human trial 2025
Altos Labs scaling research
What slows it down
Cancer risk from full reprogramming
Forecast methodology: Progress % and predicted years are computed by our proprietary algorithm combining real-money prediction markets (Polymarket, Kalshi), expert forecasts weighted by Brier score accuracy, and hard data trend extrapolation using S-curves fitted to clinical trial progression (ClinicalTrials.gov), AI benchmark scores (HuggingFace), publication velocity (arXiv), and drug approvals (openFDA). P10/P50/P90 represent optimistic, median, and pessimistic scenarios. Updated hourly.